Clearside Biomedical, Inc.
CLSDQDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
4mg CLS-TA Suprachoriodal Injection
Uveitis
CLS-AX
Neovascular Age-related Macular Degeneration
IVT aflibercept
Diabetic Macular Edema
SC CLS-TA
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
4mg CLS-TA Suprachoriodal Injection | Phase 3 | Uveitis | - | - |
CLS-AX | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
IVT aflibercept | Phase 2 | Diabetic Macular Edema | - | - |
SC CLS-TA | Phase 2 | Diabetic Macular Edema | - | - |
Frequently asked questions
What is in Clearside Biomedical, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Clearside Biomedical, Inc.'s (CLSDQ) pipeline across Phase 3, Phase 2. Its lead program is 4mg CLS-TA Suprachoriodal Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Clearside Biomedical, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Clearside Biomedical, Inc. (CLSDQ) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CLSDQ biotech catalysts?→
Add CLSDQ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Clearside Biomedical, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.